Published in final edited form as:

Schizophr Res. 2014 November ; 159(0): 370–375. doi:10.1016/j.schres.2014.08.026.

The Somatic Common Deletion in Mitochondrial DNA Is Decreased In Schizophrenia

Firoza Mamdani, PhD¹, Brandi Rollins, BSc¹, Linda Morgan, MSc¹, P. Adolfo Sequeira, PhD¹, and Marquis P. Vawter, PhD, MA, MSED^{1,*}

¹Functional Genomics Laboratory, Department of Psychiatry and Human Behavior, University of California, Irvine

Abstract

Large deletions in mitochondrial DNA (mtDNA) can occur during or result from oxidative stress leading to a vicious cycle that increases reactive oxygen species (ROS) damage, decreases mitochondrial function, thereby causing further oxidative stress. The objective of this study was to determine if disease specific brain differences of the somatic mtDNA common deletion (4,977 bp) could be observed in major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SZ) compared to a control group.

The accumulation of the mtDNA common deletion was measured using a quantitative assay across 10 brain regions (anterior cingulate cortex, amygdala, caudate nucleus, dorsolateral prefrontal cortex, hippocampus, nucleus accumbens, orbitofrontal cortex, putamen, substantia nigra, and thalamus).

The correlation with age of the mtDNA deletion was highly significant across brain regions as previously shown. A significant decrease in the global accumulation of common deletion in subjects with SZ compared to MDD, BD, and controls was observed after correcting for age, pH, PMI, and gender. The decreases in SZ were largest in dopaminergic regions. One potential side effect of antipsychotic drugs on mitochondria is the impairment of mitochondria function, which might explain these findings.

The decreased global brain mtDNA common deletion levels suggests that mitochondrial function is impaired and might be part of an overall mitochondria dysfunction signature in subjects with schizophrenia.

© 2014 Elsevier B.V. All rights reserved.

***Corresponding Author:** Marquis P. Vawter PhD, MA, MSED, Functional Genomics Laboratory, Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, CA 92697-4260, USA, Tel: 949-824-9014, mvawter@uci.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest

The authors declare no conflict of interest.

Contributors

MPV conceived of the study; FM, PAS, MPV, and BR performed analysis and wrote and edited the manuscript. PAS, BR, LM dissected brain tissue, BR conducted mtDNA deletion assays in brain and haloperidol oxygen consumption assays, LM carried out ROS study, and FM assayed common deletion in vitro. All authors reviewed and approved the manuscript.

Keywords

Mitochondrial Common Deletion; Mood disorders; Schizophrenia; Haloperidol; Mitochondrial Bioenergetics

1. Introduction

Mitochondrial functions include the production of adenosine triphosphate (ATP), maintenance of cytosolic calcium homeostasis, production and containment of reactive oxygen species (ROS), and modulation of apoptosis. These diverse mitochondrial functions are essential for neurotransmission, short- and long-term neuronal plasticity, apoptosis, aging, and behavioral adaptation. Thus, dysfunctions in these metabolic processes can play a role in a wide variety of brain diseases including mood disorders and SZ.

Deletions in mtDNA appear more frequently in tissues with high metabolic rates, such as brain and muscle (Corral-Debrinski et al., 1992; Fuke et al., 2008; Melov et al., 1999; Pak et al., 2003; Piko et al., 1988). MtDNA deletions can vary in size, decreasing energy production, and accumulate in an age dependent manner (Ballinger et al., 1992; Corral-Debrinski et al., 1992; Corral-Debrinski et al., 1991; Cortopassi and Arnheim, 1990; Cortopassi et al., 1992; Fuke et al., 2008; Kato et al., 1997; Kato and Takahashi, 1996; Meissner et al., 1997; Meissner et al., 1999; Melov et al., 1999; Piko et al., 1988; Shoffner et al., 1989). The mitochondrial common deletion is a 4,977bp deletion, spanning mtDNA 8470-13447, and flanked by two 13bp perfect repeats (Samuels et al., 2004). This common deletion (CDel) encompasses several tRNAs as well as genes encoding subunits of cytochrome oxidase, NADH dehydrogenase and ATP synthase. We and others have shown that levels of the CDel are increased in BD compared to controls, but not in SZ (Sequeira et al., 2012; Shao et al., 2008). A recent study (Torrell et al., 2013) observed higher levels of CDel in occipital cortex of MDDs and SZ compared to BD and controls, however, their results were not significant and they did not control for age, which is highly correlated with levels of the CDel in many prior studies of brain and other metabolically active tissues. Multiple lines of evidence (transcriptomic, proteomic, neuroimaging, in vitro, peripheral tissue, genetic, and animal studies) implicates mitochondrial dysfunction in mood disorders (Bezchlibnyk et al., 2001; Choudary et al., 2005; Iwamoto et al., 2005; Kato et al., 2007; Kato and Kato, 2000; Konradi et al., 2004; Rao et al., 2010; Ryan et al., 2006; Shao et al., 2008; Sun et al., 2006; Vawter et al., 2006; Washizuka et al., 2005). Recent studies have provided evidence that mtDNA sequence variants, and subsequent mitochondrial dysfunction, are associated to an increased incidence of depression (Anglin et al., 2012; Burnett et al., 2005; Fattal et al., 2006; Gardner and Boles, 2008, 2011; Gardner et al., 2003; Inczedy-Farkas et al., 2012; Rollins et al., 2009; Shao et al., 2008; Vawter et al., 2006), suggesting that mitochondrial alterations might play a role in MDD. Our own mtDNA studies have consistently showed transcriptomic alterations in postmortem brain of subjects with mood disorders and SZ (Rollins et al., 2009; Sequeira et al., 2012; Shao et al., 2008; Vawter et al., 2006). Additionally, studies of isolated mitochondria from patients with mood disorders, using peripheral tissues, have reported functional differences in calcium dynamics and energy production (Emamghoreishi et al., 2000; Emamghoreishi et al., 1997; Gardner

and Boles, 2008; Gardner et al., 2003; Iwamoto et al., 2004a; Iwamoto et al., 2004b; Kakiuchi et al., 2003; Kato et al., 2003; Naydenov et al., 2007; Washizuka et al., 2003; Washizuka et al., 2005; Wasserman et al., 2004; Xu et al., 2008).

In this study we compared the mtDNA common deletion levels in SZ, BD, and MDD to normal controls, taking into account age, gender, pH and PMI, to determine disease specific changes in the common deletion levels across 10 brain regions involved in neuropsychiatric disorders. We hypothesized that mood disorder subjects would show increased CDeI and that SZ would show no change based upon our prior work (Rollins et al., 2009; Sequeira et al., 2012; Shao et al., 2008).

2. Methods

2.1 Post-mortem human brains

Our sample consisted of 40 post-mortem human brains: MDD (N=10), BD (N=10), SZ (N=10), and psychiatrically normal controls (N=10) (Table 1, Supplemental Table 1). Brains were obtained from the University of California, Irvine Brain Bank (UCIBB). These brains have been characterized using the UCIBB psychological autopsy protocol which is based largely on procedures validated by Kelly and Mann (Kelly and Mann, 1996). A partial list of medications that were prescribed to subjects with psychiatric disorders (Supplemental Table 1) showed little consistency in medications and dosages.

For each subject, 10 brain regions were dissected: anterior cingulate cortex (ACC), amygdala (AMY), caudate nucleus (CAUN), dorsolateral prefrontal cortex (DLPFC), hippocampus (HIPPO), nucleus accumbens (NACC), orbitofrontal cortex (OFC), putamen (PUT), substantia nigra (SN), and thalamus (THAL). These regions were chosen due to their involvement in neuropsychiatric disorders.

2.2 DNA extraction

DNA was extracted from 30 mg of post-mortem brain tissue using the DNEasy Blood and Tissue DNA extraction kit (Qiagen). DNA concentration was measured using a spectrophotometer and standardized working solutions of 10 ng/μl were aliquoted in 96-well plates for ease of use during PCR.

2.3 Common deletion assay

Quantitative real time PCR (qPCR) was performed on the 7900HT real time instrument (Applied Biosystems) and two sets of primers designed around the large 4977 bp common deletion region (between 8224 and 13501) to amplify and quantify by SYBR green both the wild type and the deleted mtDNA. The deleted mtDNA sequence was amplified using DelFwd: 5'-AATCCCCCTAAAAATCTTTGAAAT-3' and WTDelRev: 5'-AACCTGTGAGGAAAGGTATTCCTGC-3'. The wild-type mtDNA sequence was amplified using WTFwd: 5'-AGGCGCTATCACCACTCTGTTCG-3' and WTDelRev. A common deletion copy number standard curve constructed using cloned standards (outlined in (Sequeira et al., 2012; Shao et al., 2008) ranging from 1,000,000 copies / μl to 100 copies / μl for wild type mtDNA, CDeI, and single copy gene (albumin). Furthermore,

detection of the common deletion was confirmed using both gel electrophoresis and Sanger sequencing.

2.4 Common Deletion Analysis

The percent common deletion (%CDel) was calculated (outlined in (Sequeira et al., 2012; Shao et al., 2008)) (Figure 1) using the following formula: $\%CDel = (\text{deletion copy number}) / (\text{deletion copy number} + \text{wild type copy number}) \times 100$. Differences in the distribution of the levels of the mitochondrial %CDel across brain regions and between diagnostic groups were carried out using Partek Genomics Suite. We conducted an analysis of covariance (ANCOVA) using PMI, pH, and age as covariates, and diagnosis and brain region as main effects.

3. Results

3.1 Mitochondrial DNA Common Deletion

In total we assayed 399 of the 400 samples taken from the 40 brains included in the study. One caudate sample was eliminated due to it being an outlier. When comparing demographic variables between groups, a small difference was found in pH between BD and controls ($p = 0.03$), no other significant difference was observed for the other demographic variables. There were no significant differences between diagnoses for post-mortem interval (PMI) or gender (Table 1). Among the covariates investigated, age was highly correlated to levels of %CDel in each brain region (Table 2), while pH and PMI showed no significant correlations with %CDel in any brain region. Because we observed a significant difference in brain pH between BD and controls, while %CDel is significantly correlated with age, knowing that there is a significant correlation of %CDel with gender (Fuke et al., 2008; Sabunciyan et al., 2007), and since PMI can be used as a proxy for autolytic degradation, all these variables (age, gender, PMI, and pH) were included in the ANCOVA model. Thus, when controlling for potential confounders we found a significant effect of Diagnosis on %CDel ($p = 0.0086$) and of Region ($p = 3.5 \times 10^{-036}$) (Table 3). The highest average levels of %CDel are found in the caudate, putamen, nucleus accumbens and the substantia nigra, three regions containing dopaminergic cell bodies or projection areas of dopaminergic axons, in line with the association between dopamine neurotransmission and accumulation of mtDNA deletions previously described (Bender et al., 2008) (Figure 2).

To determine potential diagnostic specificity, post-hoc comparative analyses were conducted. The SZ group displayed lower average global levels of %CDel when compared to each group (MDD $p < 0.001$), BD ($p < 0.02$), and controls ($p < 0.01$) (Figure 3). Since the Diagnosis $\times$ Region interaction was not significant, we did not conduct post-hoc testing of each region by diagnosis which would have increased the correction for the number of comparisons. The largest decreases between SZ and controls were observed in CAUN, SN, and PUT, followed by AMY, ACC, and DLPFC. There was a significant correlation between age and common deletion in controls ($r = 0.8$), but not in subjects with SZ ($r = 0.2$), and the difference between the correlations was significant ($p = 0.01$). This lack of an age-related increase in the common deletion in brain replicates an earlier study of individuals with SZ (Cavelier et al., 1995).

Variability in the amount of initial mitochondrial DNA across diagnoses was taken into account by direct determination of genomic DNA, using qPCR and primers directed towards the single copy gene, human albumin. A clone of the single gene albumin was used to construct standard curve for quantitative analyses. We analyzed possible main effects on the ratio of copy number of mtDNA/copy number genomic DNA and found no effects on this ratio with the Diagnosis, or Diagnosis $\times$ Region factors. For the ratio of copy number of mtDNA/copy number genomic DNA there was a significant effect of Region observed ($p < 0.0001$). Thus, the decreased amount of %CDel was not due to alterations in the starting amounts of mtDNA copy number normalized to genomic DNA copy number.

4. Discussion

Overall, the global levels of the common deletion in SZ were significantly decreased, compared to two other psychiatric groups and controls. There was no significant Diagnosis $\times$ Region interaction on common deletion levels; however the largest decreases in common deletion found in SZ compared to controls appeared most prominently in the caudate nucleus, putamen, and substantia nigra. These brain regions displaying the largest absolute decreases in the common deletion in SZ are part of the striato-nigral dopamine pathway, thus raising the question of the existence of alterations in dopamine signaling and the association between dopamine targeted antipsychotic medication and impairment of mitochondrial function.

The common deletion has been extensively studied in brain with regards to aging (Cortopassi et al., 1992; Melov et al., 1999), Alzheimer's disease (Bender et al., 2008; Lezza et al., 1999), Parkinson's (Bender et al., 2006) and BD and SZ (Fuke et al., 2008; Kakiuchi et al., 2005; Kato et al., 1997; Sabunciyan et al., 2007). Kato and colleagues first reported a significant association between increased common deletion levels and BD (Kato et al., 1997). Our results are consistent with a strong effect of age related increase of the common deletion in controls in brain. Data from our laboratory and others have shown only minimal increases in the level of the common deletion in blood with aging. The observation that the brain accumulates the common deletion with age, suggesting that the brain carries larger mitochondrial deficits across the life-span (Corral-Debrinski et al., 1992; Meissner et al., 2008; Mohamed et al., 2004; Shao et al., 2008; von Wurmb-Schwark et al., 2010; von Wurmb et al., 1998). This was well characterized by Corral-Debrinski and colleagues (Corral-Debrinski et al., 1992) when they examined CDel levels across cortical regions, the putamen and, cerebellum of control subjects with ages ranging from 24 to 94. They found greater levels of CDel in the putamen compared to the cortex, while the cerebellum demonstrated the lowest levels, as well as a strong correlation of CDel accumulation with age. Studies in psychiatric disorders have shown mixed results with regards to an age-related accumulation of CDel with several groups providing a lack of age-related accumulation in SZ (Cavelier et al., 1995; Fuke et al., 2008; Kakiuchi et al., 2005; Sabunciyan et al., 2007). In a third independent cohort reported in this paper, we have shown that considering all 40 subjects in one analysis, the human mitochondrial DNA genome accumulates the common deletion with age in brain tissue, at perhaps rates that are regionally dependent. However, when we compare the difference in correlation coefficients of common deletion and aging between schizophrenia and the control group, the control group correlation is significantly

higher. This lack of an age-related accumulation of the common deletion in SZ, and the observed significant global decrease in SZ across multiple regions might be part of the signature of mitochondrial dysfunction in SZ, consistent with multiple other reports.

Previous studies investigating the mitochondrial CDeI performed thus far in SZ have been performed in few brain regions, with the frontal cortex being the predominant region. A study by Cavelier et al (Cavelier et al., 1995) investigating levels of common deletion in the frontal cortex and caudate nucleus of subjects with Alzheimer's disease, SZ and controls. In SZ they observed differences in the amount of mitochondrial CDeI across the two brain regions, with there being higher levels in the caudate nucleus compared to the frontal cortex, in concordance with the results of our independent cohort. Fuke et al (Fuke et al., 2008) utilized a similar methodology as in this manuscript to investigate levels of CDeI in the frontal cortex of subjects with BD, SZ, and controls. The authors found no significant association of CDeI accumulation with either diagnosis, however, females presented with greater accumulation of the deletion compared to males. Similar to these results by Fuke and colleagues, Sabuncian et al (Sabuncian et al., 2007) found no significant difference in the amount of CDeI present in the frontal cortex of BD, SZ and controls; however, no effect of gender was seen.

An important factor to consider when quantifying levels of the mitochondrial CDeI is the amount of total mtDNA present and how variability in this quantity could bias the observed levels of CDeI. Studies have demonstrated the existence of variability in amounts of mtDNA between brain regions, however, this does not translate into differences between psychiatric groups and controls (Cavelier et al., 1995; Fuke et al., 2008; Sabuncian et al., 2007). A similar trend is found in this study where variability in CDeI amount is not associated with mtDNA copy number. Thus, it can be postulated that CDeI accumulation is occurring regardless of total mtDNA levels.

Limitations of post-mortem human brain studies apply to this paper, such as antipsychotic and antidepressant medications that are not quantified. It is not possible to rule out a possible impact of antidepressant or antipsychotic medication on the levels of common deletion, an animal model study would be necessary to quantify these impacts. The effects of PMI and pH, which are indicators of degradation or tissue quality, were controlled for in the main analysis, and neither the PMI nor pH correlated with the common deletion. We do not believe the differences are an artifact of autolysis and DNA degradation, after careful analysis of potential confounds of PMI and pH. Because the common deletion assay specifically detects a large deleted site (primers amplify a product across the 4,977 bp breakpoint region), the results cannot be explained by differential degradation of mtDNA across diagnoses. However, by using gross homogenates from brain regions it is not possible to determine the cellular localization of the observed levels of the common deletion. The total amount of nuclear DNA extracted was not different among diagnostic groups ruling out extraction yields and amounts of starting materials in the common deletion assay.

In conclusion, we observed significantly lower global levels of a large somatic deletion in the striato-nigral circuit of subjects with SZ. Alterations within this neural circuit have been associated with key aspects of SZ such as anhedonia, emotional valence, medication

response, and movement disorders (Der-Avakian and Markou, 2012). The likely decreased energy output of mitochondria in these brain regions could perhaps be a consequence of the medications targeting this dopaminergic neurocircuit. The presence of decreased levels of the mitochondrial common deletion in SZ subjects suggests an overall impairment of mitochondrial function, the cause or consequence of which is not clear. The decreased metabolic rate that seems to be caused by haloperidol treatment in turn results in reduced cellular energy leading to impairment of affected neurons. Further studies need to be carried out to assess the functional correlation of reduced deletion levels, mitochondrial respiration, antipsychotic medication, and its subsequent impact on brain and behavior.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

There are no acknowledgements.

Role of Funding Sources

The work within this manuscript was supported by NIH grants R01MH08580 and R21MH099440 (MPV) and R01MH097082 (PAS). The study's sponsor had no role in the study design, data collection, analysis or the interpretation and writing of the manuscript.

References

- Anglin RE, Garside SL, Tarnopolsky MA, Mazurek MF, Rosebush PI. The psychiatric manifestations of mitochondrial disorders: a case and review of the literature. *The Journal of clinical psychiatry*. 2012; 73(4):506–512. [PubMed: 22579150]
- Ballinger SW, Shoffner JM, Hedaya EV, Trounce I, Polak MA, Koontz DA, Wallace DC. Maternally transmitted diabetes and deafness associated with a 10.4 kb mitochondrial DNA deletion. *Nat Genet*. 1992; 1(1):11–15. [PubMed: 1301992]
- Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, Taylor RW, Turnbull DM. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. *Nat Genet*. 2006; 38(5):515–517. [PubMed: 16604074]
- Bender A, Schwarzkopf RM, McMillan A, Krishnan KJ, Rieder G, Neumann M, Elstner M, Turnbull DM, Klopstock T. Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions. *J Neurol*. 2008; 255(8):1231–1235. [PubMed: 18604467]
- Bezchlibnyk YB, Wang JF, McQueen GM, Young LT. Gene expression differences in bipolar disorder revealed by cDNA array analysis of post-mortem frontal cortex. *J Neurochem*. 2001; 79(4):826–834. [PubMed: 11723175]
- Burnett BB, Gardner A, Boles RG. Mitochondrial inheritance in depression, dysmotility and migraine? *Journal of affective disorders*. 2005; 88(1):109–116. [PubMed: 16019080]
- Cavelier L, Jazin EE, Eriksson I, Prince J, Bave U, Orelund L, Gyllenstein U. Decreased cytochrome-c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics. *Genomics*. 1995; 29(1):217–224. [PubMed: 8530074]
- Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, Myers RM, Bunney WE Jr, Akil H, Watson SJ, Jones EG. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. *Proc Natl Acad Sci U S A*. 2005; 102(43):15653–15658. [PubMed: 16230605]

- Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, Wallace DC. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. *Nat Genet.* 1992; 2(4):324–329. [PubMed: 1303288]
- Corral-Debrinski M, Stepien G, Shoffner JM, Lott MT, Kanter K, Wallace DC. Hypoxemia is associated with mitochondrial DNA damage and gene induction. Implications for cardiac disease. *JAMA: the journal of the American Medical Association.* 1991; 266(13):1812–1816.
- Cortopassi GA, Arnheim N. Detection of a specific mitochondrial DNA deletion in tissues of older humans. *Nucleic Acids Res.* 1990; 18(23):6927–6933. [PubMed: 2263455]
- Cortopassi GA, Shibata D, Soong NW, Arnheim N. A pattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues. *Proc Natl Acad Sci U S A.* 1992; 89(16):7370–7374. [PubMed: 1502147]
- Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. *Trends Neurosci.* 2012; 35(1):68–77. [PubMed: 22177980]
- Emamghoreishi M, Li PP, Schlichter L, Parikh SV, Cooke R, Warsh JJ. Associated disturbances in calcium homeostasis and G protein-mediated cAMP signaling in bipolar I disorder. *Biol Psychiatry.* 2000; 48(7):665–673. [PubMed: 11032978]
- Emamghoreishi M, Schlichter L, Li PP, Parikh S, Sen J, Kamble A, Warsh JJ. High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. *Am J Psychiatry.* 1997; 154(7):976–982. [PubMed: 9210749]
- Fattal O, Budur K, Vaughan AJ, Franco K. Review of the literature on major mental disorders in adult patients with mitochondrial diseases. *Psychosomatics.* 2006; 47(1):1–7. [PubMed: 16384802]
- Fuke S, Kametani M, Kato T. Quantitative analysis of the 4977-bp common deletion of mitochondrial DNA in postmortem frontal cortex from patients with bipolar disorder and schizophrenia. *Neurosci Lett.* 2008; 439(2):173–177. [PubMed: 18514404]
- Gardner A, Boles RG. Symptoms of somatization as a rapid screening tool for mitochondrial dysfunction in depression. *Biopsychosoc Med.* 2008; 2:7. [PubMed: 18294386]
- Gardner A, Boles RG. Beyond the serotonin hypothesis: Mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. *Prog Neuropsychopharmacol Biol Psychiatry.* 2011; 35(3):730–743. [PubMed: 20691744]
- Gardner A, Johansson A, Wibom R, Nennesmo I, von Döbeln U, Hagenfeldt L, Hallström T. Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. *J Affect Disord.* 2003; 76(1-3):55–68. [PubMed: 12943934]
- Incedy-Farkas G, Remenyi V, Gal A, Varga Z, Balla P, Udvardy-Meszaros A, Bereznai B, Molnar MJ. Psychiatric symptoms of patients with primary mitochondrial DNA disorders. *Behavioral and brain functions: BBF.* 2012; 8:9. [PubMed: 22329956]
- Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. *Hum Mol Genet.* 2005; 14(2):241–253. [PubMed: 15563509]
- Iwamoto K, Bundo M, Washizuka S, Kakiuchi C, Kato T. Expression of HSPF1 and LIM in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia. *J Hum Genet.* 2004a; 49(5):227–231. [PubMed: 15362566]
- Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T. Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. *Mol Psychiatry.* 2004b; 9(4):406–416. [PubMed: 14743183]
- Kakiuchi C, Ishiwata M, Kametani M, Nelson C, Iwamoto K, Kato T. Quantitative analysis of mitochondrial DNA deletions in the brains of patients with bipolar disorder and schizophrenia. *Int J Neuropsychopharmacol.* 2005; 8(4):515–522. [PubMed: 16202181]
- Kakiuchi C, Iwamoto K, Ishiwata M, Bundo M, Kasahara T, Kusumi I, Tsujita T, Okazaki Y, Nanko S, Kunugi H, Sasaki T, Kato T. Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder. *Nat Genet.* 2003; 35(2):171–175. [PubMed: 12949534]
- Kato T, Ishiwata M, Mori K, Washizuka S, Tajima O, Akiyama T, Kato N. Mechanisms of altered Ca²⁺ signalling in transformed lymphoblastoid cells from patients with bipolar disorder. *Int J Neuropsychopharmacol.* 2003; 6(4):379–389. [PubMed: 14604453]

- Kato T, Kakiuchi C, Iwamoto K. Comprehensive gene expression analysis in bipolar disorder. *Can J Psychiatry*. 2007; 52(12):763–771. [PubMed: 18186176]
- Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. *Bipolar Disord*. 2000; 2(3 Pt 1):180–190. [PubMed: 11256685]
- Kato T, Stine OC, McMahon FJ, Crowe RR. Increased levels of a mitochondrial DNA deletion in the brain of patients with bipolar disorder. *Biol Psychiatry*. 1997; 42(10):871–875. [PubMed: 9359971]
- Kato T, Takahashi Y. Deletion of leukocyte mitochondrial DNA in bipolar disorder. *Journal of affective disorders*. 1996; 37(2-3):67–73. [PubMed: 8731068]
- Kelly TM, Mann JJ. Validity of DSM-III-R diagnosis by psychological autopsy: a comparison with clinician ante-mortem diagnosis. *Acta Psychiatr Scand*. 1996; 94(5):337–343. [PubMed: 9124080]
- Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. *Arch Gen Psychiatry*. 2004; 61(3):300–308. [PubMed: 14993118]
- Lezza AM, Mecocci P, Cormio A, Beal MF, Cherubini A, Cantatore P, Senin U, Gadaleta MN. Mitochondrial DNA 4977 bp deletion and OH8dG levels correlate in the brain of aged subjects but not Alzheimer's disease patients. *FASEB J*. 1999; 13(9):1083–1088. [PubMed: 10336891]
- Meissner C, Bruse P, Mohamed SA, Schulz A, Warnk H, Storm T, Oehmichen M. The 4977 bp deletion of mitochondrial DNA in human skeletal muscle, heart and different areas of the brain: a useful biomarker or more? *Exp Gerontol*. 2008; 43(7):645–652. [PubMed: 18439778]
- Meissner C, von Wurmb N, Oehmichen M. Detection of the age-dependent 4977 bp deletion of mitochondrial DNA. A pilot study. *Int J Legal Med*. 1997; 110(5):288–291. [PubMed: 9297589]
- Meissner C, von Wurmb N, Schimansky B, Oehmichen M. Estimation of age at death based on quantitation of the 4977-bp deletion of human mitochondrial DNA in skeletal muscle. *Forensic Sci Int*. 1999; 105(2):115–124. [PubMed: 10605080]
- Melov S, Schneider JA, Coskun PE, Bennett DA, Wallace DC. Mitochondrial DNA rearrangements in aging human brain and in situ PCR of mtDNA. *Neurobiol Aging*. 1999; 20(5):565–571. [PubMed: 10638530]
- Mohamed SA, Wesch D, Blumenthal A, Bruse P, Windler K, Ernst M, Kabelitz D, Oehmichen M, Meissner C. Detection of the 4977 bp deletion of mitochondrial DNA in different human blood cells. *Exp Gerontol*. 2004; 39(2):181–188. [PubMed: 15036410]
- Naydenov A, MacDonald B, Ongur D, Konradi C. Differences in lymphocytes electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress. *Archives of General Psychiatry*. 2007; 64:555–564. [PubMed: 17485607]
- Pak JW, Herbst A, Bua E, Gokey N, McKenzie D, Aiken JM. Mitochondrial DNA mutations as a fundamental mechanism in physiological declines associated with aging. *Aging Cell*. 2003; 2(1):1–7. [PubMed: 12882328]
- Piko L, Hougham AJ, Bulpitt KJ. Studies of sequence heterogeneity of mitochondrial DNA from rat and mouse tissues: evidence for an increased frequency of deletions/additions with aging. *Mech Ageing Dev*. 1988; 43(3):279–293. [PubMed: 2849701]
- Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. *Mol Psychiatry*. 2010; 15(4):384–392. [PubMed: 19488045]
- Rollins B, Martin MV, Sequeira PA, Moon EA, Morgan LZ, Watson SJ, Schatzberg A, Akil H, Myers RM, Jones EG, Wallace DC, Bunney WE, Vawter MP. Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder. *PLoS ONE*. 2009; 4(3):e4913. [PubMed: 19290059]
- Ryan MM, Lockstone HE, Huffaker SJ, Wayland MT, Webster MJ, Bahn S. Gene expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes. *Mol Psychiatry*. 2006; 11(10):965–978. [PubMed: 16894394]
- Sabuncuyan S, Kirches E, Krause G, Bogerts B, Mawrin C, Llenos IC, Weis S. Quantification of total mitochondrial DNA and mitochondrial common deletion in the frontal cortex of patients with schizophrenia and bipolar disorder. *J Neural Transm*. 2007; 114(5):665–674. [PubMed: 17195919]

- Samuels DC, Schon EA, Chinnery PF. Two direct repeats cause most human mtDNA deletions. *Trends Genet.* 2004; 20(9):393–398. [PubMed: 15313545]
- Sequeira A, Martin MV, Rollins B, Moon EA, Bunney WE, Maciardi F, Lupoli S, Smith EN, Kelsoe J, Magnan CN, van Oven M, Baldi P, Wallace DC, Vawter MP. Mitochondrial mutations and polymorphisms in psychiatric disorders. *Frontiers in Genetics.* 2012; 3:103. [PubMed: 22723804]
- Shao L, Martin MV, Watson SJ, Schatzberg A, Akil H, Myers RM, Jones EG, Bunney WE, Vawter MP. Mitochondrial involvement in psychiatric disorders. *Annals of medicine.* 2008; 40(4):281–295. [PubMed: 18428021]
- Shoffner JM, Lott MT, Voljavec AS, Soueidan SA, Costigan DA, Wallace DC. Spontaneous Kearns-Sayre/chronic external ophthalmoplegia plus syndrome associated with a mitochondrial DNA deletion: a slip-replication model and metabolic therapy. *Proc Natl Acad Sci U S A.* 1989; 86(20):7952–7956. [PubMed: 2554297]
- Sun X, Wang JF, Tseng M, Young LT. Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. *J Psychiatry Neurosci.* 2006; 31(3):189–196. [PubMed: 16699605]
- Torrell H, Montana E, Abasolo N, Roig B, Gaviria AM, Vilella E, Martorell L. Mitochondrial DNA (mtDNA) in brain samples from patients with major psychiatric disorders: gene expression profiles, mtDNA content and presence of the mtDNA common deletion. *Am J Med Genet B Neuropsychiatr Genet.* 2013; 162B(2):213–223. [PubMed: 23355257]
- Vawter MP, Tomita H, Meng F, Bolstad B, Li J, Evans S, Choudary P, Atz M, Shao L, Neal C, Walsh DM, Burmeister M, Speed T, Myers R, Jones EG, Watson SJ, Akil H, Bunney WE. Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders. *Mol Psychiatry.* 2006; 11(7):615, 663–679. [PubMed: 16636682]
- von Wurmb-Schwark N, Schwark T, Caliebe A, Drenke C, Nikolaus S, Schreiber S, Nebel A. Low level of the mtDNA(4977) deletion in blood of exceptionally old individuals. *Mech Ageing Dev.* 2010; 131(3):179–184. [PubMed: 20117127]
- von Wurmb N, Oehmichen M, Meissner C. Demonstration of the 4977 bp deletion in human mitochondrial DNA from intravital and postmortem blood. *Mutat Res.* 1998; 422(2):247–254. [PubMed: 9838148]
- Washizuka S, Kakiuchi C, Mori K, Kunugi H, Tajima O, Akiyama T, Nanko S, Kato T. Association of mitochondrial complex I subunit gene NDUFV2 at 18p11 with bipolar disorder. *Am J Med Genet.* 2003; 120B(1):72–78. [PubMed: 12815743]
- Washizuka S, Kakiuchi C, Mori K, Tajima O, Akiyama T, Kato T. Expression of mitochondria-related genes in lymphoblastoid cells from patients with bipolar disorder. *Bipolar Disord.* 2005; 7(2):146–152. [PubMed: 15762855]
- Wasserman MJ, Corson TW, Sibony D, Cooke RG, Parikh SV, Pennefather PS, Li PP, Warsh JJ. Chronic lithium treatment attenuates intracellular calcium mobilization. *Neuropsychopharmacology.* 2004; 29(4):759–769. [PubMed: 14970832]
- Xu C, Li PP, Kennedy JL, Green M, Hughes B, Cooke RG, Parikh SV, Warsh JJ. Further support for association of the mitochondrial complex I subunit gene NDUFV2 with bipolar disorder. *Bipolar Disord.* 2008; 10(1):105–110. [PubMed: 18199248]

Figure 1.

Graph of cycle thresholds versus mitochondrial copy number for the wild type and deletion assays employed in the study to assess percent common deletion.

Figure 2.

The ten brain regions analyzed in this study showed an approximate 15 fold range of variation. The percentages are derived from copy number clones for wild type mtDNA and deleted copies.

Figure 3.

Bar graph of mean %CDel across diagnoses. Each bar is the average %CDel for each diagnosis. Significant differences between SZ and each diagnostic group, and the P-value, are displayed above each bar.

Table 1
Demographic details of the post-mortem subjects. When comparing the demographic variables between groups, pH was found to be significantly different between BD and C (p = 0.03)

Diagnosis (N)	Females (n)	Males (n)	Mean Age (Standard Deviation)	Mean pH (Standard Deviation)	Mean PMI (Standard Deviation)
BD (10)	5	5	52.4 (13.2)	6.52 (0.42)	22.98 (7.30)
C (10)	3	7	48 (13.0)	6.15 (0.19)	20.52 (8.25)
MDD (10)	7	3	47.3 (11.5)	6.40 (0.39)	24.76 (7.34)
SZ (10)	5	5	45.6 (9.0)	6.44 (0.43)	22.13 (6.38)

Table 2

Correlations between age, pH, and PMI with percent common deletion across brain regions. Only age was significantly correlated in each brain region with the common deletion, the red p-values are < 0.05. The PMI and pH were not significantly correlated with %CDel in any of 10 brain regions tested.

Brain Region	Age		pH		PMI	
	r	p-value	r	p-value	r	p-value
ACC	0.33	0.02	0.05	0.73	-0.08	0.63
AMY	0.52	0.0002	-0.05	0.72	-0.11	0.46
CAUN	0.60	0.00001	-0.03	0.87	0.01	0.94
DLPFC	0.64	0.0000019	-0.04	0.81	-0.10	0.51
HIPP	0.47	0.000895	-0.21	0.17	-0.20	0.20
NACC	0.50	0.0004	0.22	0.14	-0.07	0.65
OFC	0.64	0.000001	-0.09	0.57	-0.01	0.94
PUT	0.46	0.001	0.12	0.45	-0.03	0.87
SN	0.63	0.000002	0.13	0.38	-0.02	0.90
THAL	0.51	0.0003	-0.11	0.47	-0.02	0.90

Table 3
Main effects included in the ANCOVA model. The effect of Diagnosis was significant, while interaction of Brain Region $\times$ Diagnosis was not significant

ANCOVA Interactions and Main Effects	P-Value
Diagnosis	0.009
Age	4.83×10^{-12}
Gender	0.496
pH	0.003
Post Mortem Interval	0.328
Brain Region	3.59×10^{-36}
Brain Region $\times$ Diagnosis	0.414